Trigemina, Inc.

Organization Address
1036 Country Club Dr, Suite 200
Moraga, CA 94556

Organization Phone
(925) 377-0664



Organization Description
The concept behind our therapy is based on data demonstrating that polypeptides, when administered to the nasal mucosa, migrate along cranial nerves and are directly delivered into the central nervous system (CNS). This distinctive capacity of the cranial nerve system allows peptide-based drugs to bypass an otherwise insurmountable array of barriers in order to reach their intended targets. The direct, noninvasive pathway contrasts with other delivery routes (such as pills, patches, and intravenous administration), which are characterized by layers of physical and biochemical barriers to CNS polypeptide delivery, thus defining some of the limitations of current treatments. The ability to deliver biologics to central pain targets creates the potential for a powerful new group of drug candidates, without the typical side effects and drawbacks of opiates.

Therapeutic Areas
Central Nervous System

Drug Delivery Technologies
Drug Delivery

Clinical Development Stage